Skip to content

The Study of the effects of JingNing granule on attention deficit hyperactivity disorder

The Study of the effects of JingNing granule on Attention Deficit Hyperactivity Disorder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011042
Enrollment
Unknown
Registered
2017-04-01
Start date
2017-03-31
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder

Interventions

treatment group:JingNing granule
control group:Atomoxetine Hydrochloride

Sponsors

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 14 Years

Inclusion criteria

Inclusion criteria: (1) Conform to the diagnostic criteria for attention deficit hyperactivity disorder in Western Medicine; (2) Conforms to Qi and Yin deficiency syndrome of traditional Chinese medical differentiation standard; (3) The hyperactivity index of Conners scale is more than 1.5; (4) Aged 6 to 14 years old; (5) In the past two weeks without any psychoactive substances such as JingLing liquid,Pediatric HuangLong granule, Pemoline, Amphetamine, Cylert, Imipramine and other stimulants or tricyclic antidepressants; (6) Signed the informed consent,and voluntary take part in trial. The process of obtaining informed consent should comply with GCP regulations.

Exclusion criteria

Exclusion criteria: (1) With serious organic diseases of cardiovascular,hepatic,renal,hematopoietic and nervous system,such as chronic nephritis,hepatitis,congenital heart disease,infantile chorea,subacute encephalitis; (2) The symptoms of hearing impaired children are similar with attention deficit hyperactivity disorder; (3) The symptoms of mental retardatd children are similar with attention deficit hyperactivity disorder; (4) The symptoms of normai growing development children are similar with attention deficit hyperactivity disorder; (5) The diseases are similar with attention deficit hyperactivity disorder,such as fragile X syndrome, phenylketonuria, etc.; (6) Tourette syndrome; (7) Failure to complete the use of drugs, can not determine the efficacy or incompleted datas affect the efficacy or safety.

Design outcomes

Primary

MeasureTime frame
Digital Video EEG;Neuro Biochemistry;

Secondary

MeasureTime frame
Routine Blood Test;Routine Urine Test;Biochemistry;Electrocardiogram;

Countries

China

Contacts

Public ContactJunhong Wang

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine

Jhwang3158@126.com+86 13522958051

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026